Articles médicaux concernant les MAT

RECOMMANDATIONS Recommandations du cnr-mat publiées sous l'égide de la Société de Réanimation de Langue Française et de la Société Française d'Hématologie. ARTICLES EN FRANÇAIS L’activité de télémédecine dans les microangiopathies thrombotiques : un progrès dans les maladies rares nécessitant une prise en charge en urgence [Telemedicine in thrombotic microangiopathies: A way forward in rare diseases requiring emergency care]. Coppo P, Corre E, Rondeau E, Benhamou Y, Bachet A, Stépanian A, Veyradier A; Centre de référence des microangiopathies thrombotiques. Rev Med Interne. 2015 Dec 8. pii: S0248-8663(15)01047-4. La révolution des anticorps monoclonaux dans la prise en charge des microangiopathies thrombotiques [The revolution of monoclonal antibodies in the treatment of thrombotic microangiopathy]. Sauvètre G, Grange S, Froissart A, Veyradier A, Coppo P, Benhamou Y.Rev Med Interne. 2015 May;36(5):328-38. Purpura thrombotique thrombocytopénique et autres syndromes de microangiopathie thrombotique au cours de l’infection par le virus de l’immunodéficience humaine. Gilardin L, Malak S, Schoindre Y, Galicier L, Veyradier A, Coppo P. Rev Med Interne. 2012 Jan 24. PubMed PMID: 22280852. ADAMTS13, la protéase spécifique du clivage du facteur von Willebrand. Veyradier A, Coppo P. Med Sci (Paris). 2011 Dec;27(12):1097-105. Le syndrome hémolytique et urémique atypique: où en est-on en 2011 ? Chantal Loirat, Fadi Fakhouri, Arnaud Garnier, Frank Bienaimé, Anne-Laure Sellier-Leclerc, Véronique Frémeaux-Bacchi. Purpura thrombotique thrombocytopénique par déficit héréditaire en ADAMTS13 (syndrome d’Upshaw-Schulman) : actualités et perspectives. Veyradier A, Loirat C, Girma JP, Ribba AS, Wolf M, Coppo P, Meyer D. Hématologie 2005 ; 11 (5) : 321-34 ARTICLES EN ANGLAIS Thrombotic thrombocytopenic purpura misdiagnosed as autoimmune cytopenia: Causes of diagnostic errors and consequence on outcome. Experience of the French Thrombotic Microangiopathies Reference Centre. Grall M, Azoulay E, Galicier L, Provôt F, Wynckel A, Poullin P, Grange S, Halimi JM, Lautrette A, Delmas Y, Presne C, Hamidou M, Girault S, Pène F, Perez P, Kanouni T, Seguin A, Mousson C, Chauveau D, Ojeda-Uribe M, Barbay V, Veyradier A, Coppo P, Benhamou Y. Am J Hematol. 2017 Jan 30. doi: 10.1002/ajh.24665. Understanding therapeutic targets in thrombotic thrombocytopenic purpura. Joly BS, Vanhoorelbeke K, Veyradier A. Intensive Care Med. 2017 Jan 23. doi: 10.1007/s00134-016-4662-3. Treatment of autoimmune thrombotic thrombocytopenic purpura in the more severe forms. Coppo P; French Reference Center for Thrombotic Microangiopathies. Transfus Apher Sci. 2016 Dec 30. pii: S1473-0502(16)30205-1. Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies. Scully M, Cataland S, Coppo P, de la Rubia J, Friedman KD, Kremer Hovinga J, Lämmle B, Matsumoto M, Pavenski K, Sadler E, Sarode R, Wu H; International Working Group for Thrombotic Thrombocytopenic Purpura. J Thromb Haemost. 2017 Feb;15(2):312-322. Assessment of endothelial damage and cardiac injury in a mouse model mimicking thrombotic thrombocytopenic purpura. Le Besnerais M, Favre J, Denis CV, Mulder P, Martinet J, Nicol L, Levesque H, Veyradier A, Kopić A, Motto DG, Coppo P, Richard V, Benhamou Y. J Thromb Haemost. 2016 Oct;14(10):1917-1930. Child-onset and adolescent-onset acquired thrombotic thrombocytopenic purpura with severe ADAMTS13 deficiency: a cohort study of the French national registry for thrombotic microangiopathy. Joly BS, Stepanian A, Leblanc T, Hajage D, Chambost H, Harambat J, Fouyssac F, Guigonis V, Leverger G, Ulinski T, Kwon T, Loirat C, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Lancet Haematol. 2016 Nov;3(11):e537-e546. Efficacy of rituximab and plasmapharesis in an adult patient with antifactor H autoantibody-associated hemolytic uremic syndrome: A case report and literature review. Deville C, Garrouste C, Coppo P, Evrard B, Lautrette A, Heng AE. Medicine (Baltimore). 2016 Sep;95(39):e5007. Efficacy of a rituximab regimen based on B cell depletion in thrombotic thrombocytopenic purpura with suboptimal response to standard treatment: Results of a phase II, multicenter noncomparative study. Benhamou Y, Paintaud G, Azoulay E, Poullin P, Galicier L, Desvignes C, Baudel JL, Peltier J, Mira JP, Pène F, Presne C, Saheb S, Deligny C, Rousseau A, Féger F, Veyradier A, Coppo P; French Reference Center for Thrombotic Microangiopathies. Am J Hematol. 2016 Dec;91(12):1246-1251. [Telemedicine in thrombotic microangiopathies: A way forward in rare diseases requiring emergency care]. Coppo P, Corre E, Rondeau E, Benhamou Y, Bachet A, Stépanian A, Veyradier A; Centre de référence des microangiopathies thrombotiques. Rev Med Interne. 2016 Aug;37(8):514-20. Twice-daily therapeutical plasma exchange-based salvage therapy in severe autoimmune thrombotic thrombocytopenic purpura: the French TMA Reference Center experience. Soucemarianadin M, Benhamou Y, Delmas Y, Pichereau C, Maury E, Pène F, Halimi JM, Presne C, Thouret JM, Veyradier A, Coppo P. Eur J Haematol. 2016 Aug;97(2):183-91. Thrombotic Thrombocytopenic Purpura in Black People: Impact of Ethnicity on Survival and Genetic Risk Factors. Martino S, Jamme M, Deligny C, Busson M, Loiseau P, Azoulay E, Galicier L, Pène F, Provôt F, Dossier A, Saheb S, Veyradier A, Coppo P; French Reference Center for Thrombotic Microangiopathies. PLoS One. 2016 Jul 6;11(7):e0156679. Autoimmune thrombotic thrombocytopenic purpura associated with HHV8-related Multicentric Castleman disease. London J, Boutboul D, Agbalika F, Coppo P, Veyradier A, Gérard L, Oksenhendler E, Azoulay E, Galicier L. Br J Haematol. 2016 May 25. Epidemiology and pathophysiology of adulthood-onset thrombotic microangiopathy with severe ADAMTS13 deficiency (thrombotic thrombocytopenic purpura): a cross-sectional analysis of the French national registry for thrombotic microangiopathy. Mariotte E, Azoulay E, Galicier L, Rondeau E, Zouiti F, Boisseau P, Poullin P, de Maistre E, Provôt F, Delmas Y, Perez P, Benhamou Y, Stepanian A, Coppo P, Veyradier A; French Reference Center for Thrombotic Microangiopathies. Lancet Haematol. 2016 May;3(5):e237-45. The European Hematology Association Roadmap for European Hematology Research: a consensus document. Engert A, Balduini C, Brand A, Coiffier B, Cordonnier C, Döhner H, de Wit TD, Eichinger S, Fibbe W, Green T, de Haas F, Iolascon A, Jaffredo T, Rodeghiero F, Salles G, Schuringa JJ; EHA Roadmap for European Hematology Research. Haematologica. 2016 Feb;101(2):115-208. Von Willebrand Factor--A New Target for TTP Treatment? Veyradier A. N Engl J Med. 2016 Feb 11;374(6):583-5. [Thrombotic thrombocytopenic purpura in a newborn]. hariani I, Jmili-Braham N, Azzebi O, Kortas M, Veyradier A, Bakir L. Arch Pediatr. 2016 Jan;23(1):78-81. Treatment of thrombotic thrombocytopenic purpura beyond therapeutic plasma exchange. Coppo P, Froissart A; French Reference Center for Thrombotic Microangiopathies. Hematology Am Soc Hematol Educ Program. 2015 Dec 5;2015(1):637-43. Rituximab in autoimmune thrombotic thrombocytopenic purpura: A success story. Froissart A, Veyradier A, Hié M, Benhamou Y, Coppo P;